Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Omeros Corp

OMER ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$19.27

▲ +3.44%

Market Cap $1.39B · Vol 934.32K

Key Metrics

P/E Ratio

13.30

FWD: 20.87

Market Cap

$1.39B

Small Cap

Div Yield

N/A

EPS Growth

+1,700.00%

YoY

RSI (14)

91.99

Momentum

Beta

2.58

vs Market

52W High

$19.57

1.53% below

52W Low

$3.94

389.09% above

Volume

934.32K

Avg 654.74K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

95.92%

Public shares

Shariah Compliance8 STANDARDS

✗ Omeros Corp (OMER) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OMER pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.10%

+102.20%

+61.12%

+60.05%

YTD

+12.20%

+330.13%

+419.41%

+30.47%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-4,808,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-0.93% · N/A

P/E Ratio	13.30
Forward P/E (FY1)	20.87
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+1,700.00%
Outstanding Shares	72.39M

Technical Indicators

50-Day SMA	$11.72
200-Day SMA	$11.55
RSI (14)	91.99
Beta	2.58
52-Week High	$19.57
52-Week Low	$3.94

Volume Today	934.32K
Avg Daily Volume (30D)	654.74K
Relative Volume	1.43x
Volatility (10D)	109.98
Volatility (30D)	93.07
Free Float	95.92%

Analyst Consensus

BUY

Current Price $19.27

Mean Target $44.00

52W Low$3.94 52W High$19.57

Current

Target

$3.94 $19.57

Current Analyst target

+128.33% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SPJH21

ISINUS6821431029

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.39% ARGX.BR argenx SE +1.90% ARGX argenx SE +0.16% INSM Insmed Inc +0.55% 2269.HK WuXi Biologics (Cayman) Inc +2.74%

Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.